arrow_back Back to App

End Drug Price Gouging: Establishing Reference Prices for Federal Health Programs.

This act aims to lower prescription drug prices by setting maximum prices that manufacturers cannot exceed. It applies to drugs purchased under federal health programs like Medicare and Medicaid, as well as for uninsured individuals. The goal is to ensure that medications are more accessible and affordable for all citizens.
Key points
Establishment of maximum prescription drug prices based on prices in other countries or therapeutic value.
Reduction of drug costs for individuals covered by federal health programs (e.g., Medicare, Medicaid, TRICARE, VA, FEHBP, Indian Health Service).
Drug manufacturers will be required to offer drugs at the established reference price to everyone, including uninsured individuals.
Financial penalties for manufacturers who do not comply with the new rules, with collected funds allocated to drug research.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_S_1323
Sponsor: Sen. Merkley, Jeff [D-OR]
Process start date: 2021-04-22
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

End Price Gouging for Medications Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_S_1323.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2021-04-22.

What are the main provisions?

Key points include:

  • Establishment of maximum prescription drug prices based on prices in other countries or therapeutic value.
  • Reduction of drug costs for individuals covered by federal health programs (e.g., Medicare, Medicaid, TRICARE, VA, FEHBP, Indian Health Service).
  • Drug manufacturers will be required to offer drugs at the established reference price to everyone, including uninsured individuals.
  • Financial penalties for manufacturers who do not comply with the new rules, with collected funds allocated to drug research.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Merkley, Jeff [D-OR].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

CATEGORIES

Health